Role of BNP and echo measurement for pulmonary hypertension recognition in patients with interstitial lung disease: An algorithm application model

Respir Med. 2015 Mar;109(3):406-15. doi: 10.1016/j.rmed.2014.12.011. Epub 2015 Jan 3.

Abstract

Background: This study evaluated the role of echocardiography and BNP in patients with interstitial lung disease (ILD), to identify those with PH and RV dysfunction. The aims of this study were: 1-to evaluate the accuracy of an algorithm including BNP, DLCO and echocardiographic measurements to identify PH and RV dysfunction; 2- to evaluate BNP and Echo values concordance in relation to right catheterization measurement.

Methods: We analyzed 113 patients with diagnosis of ILD. Echo examination included: Pulmonary systolic, diastolic and mean Arterial Pressure (PAPs, PAPd, PAP mean), End-Diastolic and End-Systolic right ventricle diameters, Inferior Caval Vein diameter, and Tricuspid Annular Plane Systolic Excursion (TAPSE). Patients revealing increased PAPs at echocardiography underwent to catheterization.

Results: Patients with PAPs > 40 mm Hg (37 patients), PAPmean ≥ 25 mm Hg (23 patients) and PAPd ≥ 20 mm Hg showed BNP increased (157 ± 96 vs 16 ± 14 pg/ml p = 0.004; 201 ± 120 vs 28 ± 17 pg/mL; 124 ± 88 vs 23 ± 18 pg/ml p < 0.001) as patients with TAPSE ≤16 mm (25 patients) (145 ± 104 vs 26 ± 21 pg/ml p < 0.001). In catheterized patients (37 patients) BNP was increased in patients with invasive PAPs > 40 mm Hg (165 ± 112 vs 29 ± 14 pg/ml p < 0.02), as well as in patients with Wedge pressure > 14 mm Hg (199 + 153 vs 54 + 39 pg/mL; p = 0.01). ROC Curve analysis showed that elevated values of BNP, PAPs, PAP mean are able to assess PH. On the other hand, lower values of DLCO (<40%) and TAPSE (≤16 mm) detect PH. Logistic regression analysis of the previous parameters, confirmed their diagnostic role in PH detection.

Conclusions: In patients with ILD, an algorithm including BNP, DLCO and echocardiography could be useful for non invasive screening of PH.

Clinical trial registration name and number: ARTEMIS-HP trial; ID number: NCT00879229.

Keywords: BNP; Diagnostic methods; Interstitial lung disease; Pulmonary hypertension.

MeSH terms

  • Aged
  • Algorithms
  • Biomarkers / blood
  • Diagnosis, Differential
  • Echocardiography, Doppler*
  • Female
  • Humans
  • Hypertension, Pulmonary / blood
  • Hypertension, Pulmonary / diagnosis*
  • Hypertension, Pulmonary / epidemiology
  • Hypertension, Pulmonary / etiology
  • Italy / epidemiology
  • Lung Diseases, Interstitial / blood
  • Lung Diseases, Interstitial / complications
  • Lung Diseases, Interstitial / diagnosis*
  • Lung Diseases, Interstitial / epidemiology
  • Male
  • Middle Aged
  • Natriuretic Peptide, Brain / blood*
  • Patient Selection
  • Prevalence
  • Retrospective Studies
  • Risk Factors
  • Severity of Illness Index
  • Tertiary Care Centers

Substances

  • Biomarkers
  • Natriuretic Peptide, Brain

Associated data

  • ClinicalTrials.gov/NCT00879229